An automated method based on column-switching reversed-phase in high-performance liquid chromatography the heart-cutting mode has been developed for the simultaneous determination of the two major human metabolites of tipredane, FPL 66365XX and FPL 66366XX, in human urine. The limit of quantification of the method was 25 ng/ml for both analytes from a urine injection volume of 100 microl. The intra- and inter-assay precision and accuracy were acceptable between 25 and 5000 ng/ml. No significant interferences were observed from either tipredane or a selection of its putative metabolites, or urine constituents in samples from male and female volunteers. Both analytes were found to be stable in human urine when stored at room temperature for two days, at 4 degrees C for six days, in a freezer at or below -20 degrees C for three weeks, and when the urine samples were subjected to three freeze-thaw cycles The method was unusual in that the initial separation was performed on a non-polar, octadecylsilane, column and the final separation on a more polar, trimethylsilane column. These columns were selected only after the investigation of a wide range of reversed-phase columns. The method's success was based on the greatly differing selectivities shown towards the two analytes by the organic modifiers, methanol and acetonitrile, present in the mobile phases used for the extraction and analytical stages

1995-07-01·Journal of the American Chemical Society

FKBP12-ligand-calcineurin interactions: analogs of SBL506

作者: Furber, Mark

Described in this communication are the synthesis and biol. activities of two close analogs [(3) and (4)] of SBL506 (Structure-Based Design of an Acrylic Ligand That Bridges FKBP12 and Calcineurin - J. Am. Chem. Soc. 19993, 115, 10420-10421).The impetus for the present work was the remarkable biol. activity reported for SBL506 itself.Addnl., a novel and efficient 3-step procedure for incorporating the diketoamide unit present (in latent form) in mols. of this type (including FK506 and rapamycin themselves) is described - see retrosynthetic scheme.This procedure will be of great interest to synthetic chemists working the FK506 and rapamycin area.

1994-05-01·British Journal of Pharmacology

Characterization of the prostaglandin E₂ sensitive (EP)‐receptor in the rat isolated trachea

Article

作者: McKechnie, K. ; Lydford, S. J.

Using a range of natural and synthetic prostanoid receptor agonists and antagonists, we have shown that the rat isolated trachea contains a heterogeneous population of prostaglandin receptor sub‐types mediating both relaxation and contraction of the smooth muscle. Prostaglandin E2 (PGE2) elicits smooth muscle relaxation of pre‐contracted preparations, the responses being well defined, with a mean potency (p[A50]) of 7.81 ± 0.05.

11‐deoxy PGE1 16,16‐dimethyl PGE2 and misoprostol were all full agonists at this receptor, whilst AH13205 was a low potency agonist, and sulprostone was inactive.

The EP1 receptor antagonist, AH6809 (5 μm), and the selective DP receptor antagonist, BW A868C (0.1 μm), had no significant effect on the concentration‐effect (E/[A]) curves to PGE2.

The putative EP4‐receptor antagonist, AH23848B, produced non‐competitive antagonism of the PGE2 response curves; pA2 values of 5.07 ± 0.15 and 5.24 ± 0.19 were obtained at concentrations of 30 μm and 100 μm respectively.

The synthetic thromboxane A2 mimetic, U46619, caused smooth muscle contractions, with a mean p[A50] of 6.90 ± 0.11. This response was antagonized by the TP receptor antagonist, GR32191B, yielding a mean pA2 of 8.31.

At concentrations of 1 μm and above, prostaglandin D2 (PGD2) and the IP‐receptor agonist, cicaprost, generally elicited concentration‐dependent relaxations of the rat trachea. Prostaglandin F2α (PGF2α) was without affinity or efficacy.

These data suggest that the rat isolated trachea contains EP‐receptors, TP‐receptors, and few, if any, DP, IP or FP‐receptors. The inactivity of sulprostone (EP3/EP1 receptor selective) and the low potency of AH13205 (EP2‐receptor selective) suggest that the rat trachea contains an atypical EP‐receptor that does not conform to the current classification system.

项与 Fisons Plc 相关的新闻（医药）

2022-06-07

·BioSpace

Asthma Spacers Market Trend - Rising Government Initiatives to Raise Awareness About Severe Respiratory Diseases

Increasing incidence of various respiratory diseases, rising investments on developing advanced products and devices, and growing awareness about importance of using asthma spacers are some key factors expected to drive global Asthma Spacers market growth. According to Emergen Research, the global asthma spacers market size was USD 1.85 billion in 2019 and is expected to reach USD 2.38 billion in 2027 and register a steady revenue CAGR of 3.4% during the forecast period, 2020-2027. Market Dynamics: Asthma is a chronic respiratory condition in which air passages in the lungs become narrow due to tightening and inflammation of the muscles around the airways. Millions of children and adults across the globe suffer from asthma. This condition cannot be completely cured, but good management with inhaled medications and drugs can help in controlling it. Inhalers are the most commonly used medication for asthma. Asthma spacers are extremely useful while using these inhalers or puffers. Request Free Sample Copy (To Understand the Complete Structure of this Report [Summary + TOC]) @ An asthma spacer is a tube-shaped holding chamber, used for making the aerosolized medication administration from a metered-dose inhaler easy. These spacers help in delivering the medication straight to the lungs, thereby resulting in fewer doses in throat and mouth. Factors such as increasing prevalence of chronic obstructive pulmonary disease, asthma, sleep apnea, and lung cancer globally, rising availability of various types of asthma spacers in the market, and increasing levels of air pollution worldwide are expected to drive global market revenue growth. However, high costs of asthma spacers and low awareness about these spacers especially in the developing and underdeveloped economies are some key factors that can hamper overall market growth to a certain extent during the forecast period. COVID-19 Impact Analysis: Social distancing and restrictions severely disrupted businesses and operations Lockdowns caused disruptions in transportation and logistics Impacted manufacturing activities and mining operations globally Took a toll on economy of various countries Caused sudden and drastic downturn in economic activity Disrupted agriculture, fisheries, dairy, and other sectors Caused loss of employment and financial crisis Supply impacts were further compounded owing to reduced disposable income Emergence of variants continue to cause concerns and impact normal routines Aerochamber Segment To Account for Largest Revenue Share: The aerochamber segment is expected to account for largest revenue share between 2020 and 2027 owing to large patient pool, growing demand for convenient and user-friendly products, and high demand for aerochambers among patients with face difficulties in coordinating hand to mouth techniques. Browse Full Report Description + Research Methodology + Table of Content + Infographics@ Homecare Segment to Register Rapid Revenue CAGR: The homecare segment is expected to register rapid revenue CAGR over the forecast period owing to rising prevalence of chronic pulmonary diseases, increasing geriatric population, and rising availability of various types of advanced and user-friendly spacers. North America to Lead In Terms of Revenue Share: North America is expected to dominate other regional markets in terms of revenue share during the forecast period owing to increasing prevalence of respiratory diseases across the region, rising levels of pollution, and rising investments by public and private organizations for the development of advanced and innovative products. Major Companies in the Market Include: Lupin Limited Trudell Medical Group Ltd. GlaxoSmithKline plc Cipla Limited Merck & Co., Inc. Clement Clarke International Ltd PARI GmbH AstraZeneca plc/AB Fisons plc Allergan plc Emergen Research is Offering Limited Time Discount (Grab a Copy at Discounted Price Now) @ For the purpose of this report, Emergen Research has segmented the global asthma spacers market on the basis of type, distribution channel, end-use, and region: Type Outlook (Revenue, USD Billion; 2017-2027) Inspirease Optichamber Aerochamber Volumatic Distribution Channel Outlook (Revenue, USD Billion; 2017-2027) E-commerce Retail Pharmacy Hospital Pharmacy End-Use Outlook (Revenue, USD Billion; 2017-2027) Homecare Clinics & Hospitals Others Regional Outlook (Revenue, USD Billion; 2017–2027) North America U.S. Canada Mexico Europe Germany France U.K. BENELUX Italy Rest of Europe Asia Pacific China India Japan South Korea Rest of APAC Latin America Brazil Rest of LATAM Middle East & Africa Saudi Arabia U.A.E. South Africa Turkey Rest of MEA Looking to Purchase Reports in Bundle [Schedule a Call with An Analyst]@ Read Latest Reports Published by Emergen Research: Head-up Display Market Deep Brain Stimulation Systems Market In-Vitro Fertilization Market Next-Generation Sequencing Market Cell Culture Market Interoperability Solutions in Healthcare Market New-born Screening Market Food Cold Chain Market Molecular Diagnostics Point of Care Market Adaptive Learning Market About Emergen Research Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trend’s existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors. Contact Us: Eric Lee Corporate Sales Specialist Emergen Research | Web: Direct Line: +1 (604) 757-9756 E-mail: sales@emergenresearch.com Visit for More Insights: Explore Our Custom Intelligence services | Growth Consulting Services Press Release Available @

100 项与 Fisons Plc 相关的药物交易

登录后查看更多信息

100 项与 Fisons Plc 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

或

查看完整样例数据

管线布局

2025年02月19日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

药物发现

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

FPL-64176 ( calcium channel )	心脏衰竭更多	药物发现
氨茶碱 ( cGMP-PDE )	-	撤市
FPL-65372 ( Proton pump )	消化性溃疡更多	终止
乌替普利 ( ACE )	高血压更多	终止
Zemaphyte ( NF-κB )	湿疹更多	终止